Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

Autor: Kevin K. Brown, Yoshikazu Inoue, Kevin R. Flaherty, Fernando J. Martinez, Vincent Cottin, Francesco Bonella, Stefania Cerri, Sonye K. Danoff, Stephane Jouneau, Rainer‐Georg Goeldner, Martin Schmidt, Susanne Stowasser, Rozsa Schlenker‐Herceg, Athol U. Wells

Publikováno v: Respirology
Respirology, 2022, 27 (4), pp.294-300. ⟨10.1111/resp.14231⟩

International audience; Background and objective Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42f11f29b919d8ce03a849a468d40931
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85125387576

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

Autor: Martin Kolb, Dirk Koschel, Yoshikazu Inoue, Kevin K. Brown, Athol U. Wells, Simon L.F. Walsh, Luca Richeldi, Susanne Stowasser, Anand Devaraj, Teng Moua, Vincent Cottin, Rainer-Georg Goeldner, Kevin R. Flaherty, Rozsa Schlenker-Herceg

BackgroundThe primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a33e08941ead9543b75d0c310a4197
http://hdl.handle.net/10807/187360

Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib?

Autor: Yoshikazu Inoue, Susanne Stowasser, Bruno Crestani, Athol U. Wells, Vincent Cottin, Luca Richeldi, Rainer-Georg Goeldner, Maria Molina Molina, Rozsa Schlenker-Herceg

Publikováno v: ILD / DPLD of known origin.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b382495492617155dce95ced60db2514
https://doi.org/10.1183/13993003.congress-2020.740

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Autor: Rainer Georg Goeldner, S. Abe, Dirk Skowasch, Romain Kessler, S. Izumi, A. Barczyk, E. Belloli, J. S. Park, H. Takaya, C. Marquette, Neil Ettinger, Krishna Thavarajah, Nina Patel, Manuel Quaresma, Yasuhiko Nishioka, D Koschel, Silvia Quadrelli, M. A. Bergna, J. Sauleda, M. Salinas Fénero, J. Kang, G. Giessel, Oksana A. Shlobin, Kevin K. Brown, T. Kawamura, Ketan P. Buch, W. Randerath, O. Acosta, A. Silva Orellana, L. Wemeau, N. Sakamoto, Bruno Crestani, Sonye K. Danoff, Shane Shapera, S. Stieglitz, M. Reynaud-Gaubert, Tejaswini Kulkarni, P. Elias, Leslie Tolle, Lake Morrison, C. Glazer, Yoshikazu Inoue, Rozsa Schlenker-Herceg, Yolanda Mageto, Anand Devaraj, Zeenat Safdar, H. Hayashi, Y. Kim, Nik Hirani, Srihari Veeraraghavan, Sylvain Marchand-Adam, S. Cerri, J. Golden, D. Hotchkin, Rebecca Bascom, K. Ichikado, Martin Kolb, Nazia Chaudhuri, H. Cai, B. Crestani, J. W. Song, V. Yakusevich, Anoop M. Nambiar, Sergey Moiseev, Y. Kondoh, F. Lebargy, Wim A. Wuyts, Maria Padilla, A. Gamez-Dubuis, Sergey Avdeev, A. León Jiménez, R. Martinez, Luca Richeldi, J. Dematte D'Amico, Teng Moua, E. Bergot, J. Falk, Benjamin Bondue, K. Kishi, Danielle Antin-Ozerkis, L. Gómez Carrera, Francesco Bonella, Vincent Cottin, T. Moua, A. Villar, Stéphane Jouneau, Z. Xu, R. Hallowell, Mary E. Strek, H. Takahashi, Antje Prasse, A. Cantin, M. Okamoto, G. Criner, M. Rossman, M. Schwartz, R. Refini, Myriam Aburto, S. Makino, Y. Inoue, L. Jones, J. Burk, L. Morrow, Shelley L. Schmidt, S. Chaaban, M. Ilkovich, J. A. Rodríguez Portal, Athol U. Wells, S. Blaas, C. Andrews, D. M. Castillo Villegas, Caroline Dahlqvist, Q. Luo, H. Yamauchi, Justin M. Oldham, Julien Guiot, M. Kolb, Nitin Y. Bhatt, Y. Yamada, Maria Otaola, Alberto Pesci, E. Britt, W. Wuyts, E. Jassem, Daniel F. Dilling, Kevin R. Flaherty, H. Kitamura, H. Poonyagariyagorn, Y. Miyazaki, Robert J. Kaner, L. Pitts, Toby M. Maher, Marilyn K. Glassberg, G. Arce, J. Kus, S. Weigt, E. R. Fernández Pérez, Ivan O. Rosas, Michael Kreuter, Claudia Valenzuela, S. Tomassetti, Susanne Stowasser, K. Tomii, C. Kono, Ben Hope-Gill, D. Ziora, B. Sigal, E. Bazdyrev, R. Maturana Rozas, Paul Beirne, T. Saito, F. Varone, T. Suda, M. Arias, A. Cazaux, J. Hetzel, Helen Stone, Maria Molina-Molina, F. Riviere, L. Homik, Mary Beth Scholand, A. Gifford, W. Piotrowski, Carlo Vancheri, T. Takeuchi, H. Sugiura, M. Martínez, Hilario Nunes

Publikováno v: The Lancet. Respiratory medicine, 8 (5

The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12fb103566afe883ea90e5352d7b9ae8
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/305426

Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial*

Autor: Anand Devaraj, Y. Inoue, Vincent Cottin, Kevin R. Flaherty, Susanne Stowasser, Emmanuelle Clerisme-Beaty, Simon L.F. Walsh, Luca Richeldi, Rozsa Schlenker-Herceg, Athol U. Wells, Carl Coeck, D Koschel, Kevin K. Brown, Rainer-Georg Goeldner

Publikováno v: 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3acc54c8a44987f300a020a9a7680462
https://doi.org/10.1055/s-0039-3403297